Silverback therapeutics website trial#
Silverback therapeutics website free#

securities, and/or would like to discuss your legal rights and options please visit or contact Joe Seidman toll free at (877) 779-1414 or 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. If you purchased or acquired Silverback Therapeutics, Inc. If you choose to take no action, you may remain an absent class member. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

If you wish to serve as lead plaintiff, you must move the Court no later than January 4, 2022. On this news, Silverback's stock price fell $4.54 per share, or 23.35%, to close at $14.90 per share on September 13, 2021. The accepted abstract revealed that while there was a manageable safety profile for the Company's experimental therapy, SBT6050 yielded only one partial response among 14 HER2-positive solid tumors.

Silverback therapeutics website trial#

On September 13, 2021, Silverback issued a press release 'announc that interim data from the dose-escalation portion of its Phase 1/ 1b clinical trial evaluating SBT6050 as a monotherapy and in combination with pembrolizumab in patients with advanced or metastatic HER2-expressing or amplified solid tumors' were to be presented from September 16-21, 2021. Shareholder Class Action Lawsuit or contact Joe Seidman toll free at (877) 779-1414 or or about December 3, 2020, Silverback conducted its IPO, offering 11,500,000 shares of its common stock to the public at a price of $21 per share for anticipated proceeds of approximately $241,500,000.Īccording to the complaint, Defendants made false and/or misleading statements and failed to disclose that (i) Silverback's lead product candidate SBT6050 was less effective than the Company had represented to investors and (ii) the Company had overstated SBT6050's commercial and/or clinical prospects. If you purchased or acquired (a) Silverback common stock in connection with the IPO and/or (b) Silverback securities during the Class Period, and/or would like to discuss your legal rights and options please visit Silverback Therapeutics Inc. (PRNewsFoto/Bernstein Liebhard LLP) (PRNewsfoto/Bernstein Liebhard LLP)